Virios Therapeutics (NASDAQ:VIRI) Shares Down 2.6% – What’s Next?

Virios Therapeutics, Inc. (NASDAQ:VIRI)’s stock price fell 2.6% on Tuesday . The company traded as low as $6.33 and last traded at $6.35. 12,813 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 1,049,645 shares. The stock had previously closed at $6.5201.

Virios Therapeutics Stock Down 2.6%

The stock’s 50 day moving average is $6.04 and its two-hundred day moving average is $5.33. The company has a market capitalization of $122.29 million, a PE ratio of -23.52 and a beta of 1.58.

Virios Therapeutics Company Profile

Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.